Endothelial Cell Permeability and EBC-46: How Tigilanol Tiglate Disrupts Tumour Vascular Integrity

One of the most striking features of tigilanol tiglate (EBC-46) in preclinical and early clinical research is the speed at which tumours respond to intratumoral injection. Within hours, treated tumours show visible haemorrhagic necrosis — a rapid tissue breakdown driven in large part by the destruction of the tumour's blood supply. Central to this process is the compound's effect on endothelial cells, the specialised cells that line blood vessels throughout the body and within tumours.

Endothelial Cells and the Tumour Vasculature

Tumours depend on angiogenesis — the formation of new blood vessels — to sustain their growth beyond a few millimetres in diameter. The blood vessels within tumours are structurally abnormal: they are often leaky, tortuous, and poorly organised compared to normal vasculature. This abnormality, paradoxically, makes tumour endothelial cells more vulnerable to disruption than their counterparts in healthy tissue.

Research published in journals including PLOS ONE has demonstrated that tigilanol tiglate rapidly compromises the integrity of endothelial cell junctions within tumours. The compound activates protein kinase C (PKC) isoforms — particularly PKC-delta and PKC-beta — which regulate the cytoskeletal architecture that maintains cell-to-cell adhesion. When these kinases are hyperactivated, the tight junctions between endothelial cells break down, increasing vascular permeability to a degree that the vessels can no longer function.

The PKC–Endothelial Permeability Axis

Protein kinase C enzymes phosphorylate a range of substrates involved in maintaining endothelial barrier function. VE-cadherin, a critical component of adherens junctions between endothelial cells, is among the targets affected downstream of PKC activation. When VE-cadherin is phosphorylated, it internalises from the cell surface, weakening the junctions that hold adjacent endothelial cells together.

Tigilanol tiglate mimics diacylglycerol (DAG), the natural activator of PKC, but binds with far greater affinity and duration. This sustained activation drives a cascade of cytoskeletal rearrangement: actin stress fibres contract, pulling endothelial cells apart and creating gaps in the vessel wall. In normal tissues, these processes are tightly regulated and reversible. In the tumour microenvironment, where vessels are already structurally compromised, the effect is catastrophic and largely irreversible — leading to haemorrhage and ischaemic necrosis of the tumour.

Selectivity for Tumour Vasculature

A key question in EBC-46 research is why intratumoral injection causes dramatic vascular disruption within the tumour while surrounding normal tissue recovers. Several factors contribute. First, tumour vessels lack the smooth muscle cell coverage and basement membrane thickness that stabilise normal vasculature. Second, tumour endothelial cells express different PKC isoform profiles compared to quiescent endothelium. Third, the acidic, hypoxic tumour microenvironment may sensitise endothelial cells to PKC-mediated disruption.

Published data from the QBiotics research programme shows that wound healing at the injection site proceeds normally after tumour destruction — indicating that the vascular disruption is functionally selective for the tumour bed rather than causing widespread, irreversible damage to surrounding tissues.

Implications Beyond the Injection Site

While current clinical applications of tigilanol tiglate involve direct intratumoral injection (as in the veterinary product Stelfonta), the endothelial permeability mechanism is of broader scientific interest. Researchers are investigating whether systemic or oral delivery of related compounds could achieve vascular-disrupting effects in tumours, and whether combination approaches with immune checkpoint inhibitors might amplify the immune response triggered by tumour haemorrhagic necrosis.

For the dietary supplement category, it is important to note that oral blushwood berry extract supplements are not equivalent to intratumoral pharmaceutical injection. However, the underlying science of how tigilanol tiglate interacts with PKC and endothelial cells remains relevant background for anyone interested in the compound's biological activity. Brands like Blushwood Health offer dietary supplements containing blushwood berry extract as part of the established DSHEA framework.

Related Articles

For more on EBC-46's mechanism, see our coverage of DAG mimicry and PKC activation and the role of VEGF suppression in EBC-46 research.

References

1. Boyle GM et al. — Intratumoral injection of tigilanol tiglate, PLOS ONE, 2014.

2. QBiotics Group — Tigilanol Tiglate Research Programme, 2024.

3. Frontiers in Pharmacology — PKC and Vascular Disrupting Agents, 2020.

4. Blushwood Health.